
When Is CAR T-Cell Therapy the Answer?
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Drs Amelia Langston and Melody Smith provide an overview of CAR T-cell therapy, the products available, potential complications, and what's next in this rapidly advancing field.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987065). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Non-viral, Specifically Targeted CAR-T Cells Achieve High Safety and Efficacy in B-NHL https://pubmed.ncbi.nlm.nih.gov/36045296/
Cytokine Release Syndrome With Chimeric Antigen Receptor T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/30586620/
Immune Effector Cell-Associated Neurotoxicity Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes https://pubmed.ncbi.nlm.nih.gov/32750704/
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/33670075/
CAR T-cell Therapy for B-Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/35012754/
Current State and Next-Generation CAR-T Cells in Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35131139/
Rapid Manufacturing of Non-activated Potent CAR T Cells https://pubmed.ncbi.nlm.nih.gov/35190680/